Top Health Tools
Top Health Tools

Top Reports
Top Reports
Top Articles
Top Articles

Top Reviews
Top Reviews
WHO Still Recommends Tamiflu For
H1N1 Despite The Proof It's Useless

Ironically, the World Health Organization (WHO), the agency responsible for the H1N1 flu, vaccine and antiviral hype, is now endorsing findings that there is no clear evidence the antiviral Tamiflu prevents complications such as pneumonia in otherwise healthy people with seasonal flu.

Despite this evidence, and to coincide with the WHO's junk science and contradictions which have dominated their pandemic statements and policies, they continue to recommend that Tamiflu be used in people infected with the H1N1 virus.

The WHO also said pandemic influenza has peaked in North America, most of Western Europe except France, and possibly in Russia as well, the WHO said in a weekly statement.

An updated review in the Cochrane Review published by the British Medical Journal, researchers found there was insufficient data to know if the drug cut complications from flu.

Roche, the manufacturer of Tamiflu, has made it impossible for scientists to assess how well the anti-flu drug stockpiled around the globe works by withholding the evidence the company has gained from trials, doctors alleged.

"We would not take issue with the Cochrane conclusions concerning seasonal influenza," WHO spokesman Gregory Hartl said.

Hartl told Reuters: "That is entirely consistent with our views and guidelines. For otherwise healthy people presenting with uncomplicated seasonal influenza, they do not need to be treated with the drugs."

Roche has contested the finding and said it stood behind the previous data showing a benefit.

At issue is whether or not certain previously published trials on Tamiflu should be included or excluded when analysing the drug's effectiveness.

In direc contradiction to his previous statements, Hartl then said that in the course of the H1N1 pandemic, "a substantial body of evidence has been building up to indicate oseltamivir is effective at reducing and/or preventing severe illness and even death."

This was mainly in people who are at higher risk from H1N1 due to underlying medical conditions such as asthma or in patients who develop severe illness, he said.

"So our recommendations have been and continue to be that concerning infections with H1N1, if you are in a high risk group you should start oseltamivir treatment immediately."

Other experts have noted that evidence also suggests that Tamiflu and other antivirals lower body temperatures. They make people (who can still transmit the virus) asymptomatic for longer periods and can therefore be expected to facilitate and contribute to the spread of the pandemic. If populations begin taking Tamiflu as a preventive measure, it could potentially cause the reverse of the intended effect, causing an explosion of viral transmission.

"If you are not in a high risk group but if you have symptoms which persist over 3 days and or get worse, you should begin oseltamivir treatment," the WHO said.

In early 2008, the WHO began stating on their own website that they had reported a high rate of resistance to Tamiflu. A total of 30 countries from all WHO regions reported Tamiflu (oseltamivir) resistance for H1N1. Since then, the WHO has been suspiciously downplaying the rapid growth of mutations and antiviral resistance. Some experts suggest that the number of actual cases of antiviral resistance are far higher than those being reported by the WHO.

Despite the adverse reactions of antivirals such as Tamiflu, and their use consistently reporting pneumonia and respiratory failure, the WHO's recommendation is to administer these drugs antivirals to people who have already developed pneumonia, an endorsement that could potentially promote millions of fatalities.

The World Health Organization also said last month that H1N1 vaccine had been cleared of blame for 41 deaths which health authorities worldwide had investigated after suspicions they might have been caused by the inoculation. The agency reaffirmed that the pandemic vaccine is as safe as the seasonal flu vaccine.

"No new safety issue has been identified from reports issued to date ... Reporting so far reconfirms that the pandemic flu vaccine is as safe as the seasonal flu vaccine," Marie-Paule Kieny, WHO's top vaccine expert, told a telephone conference.

Perhaps the 2300 reports of adverse reactions from the pandemrix vaccine in Sweden, the plethora of miscarriages, paralyses and other reactions from around the world, and the 200 deaths in Canada in addition to the 170,000 doses recalled due to safety issues all went unnoticed by the WHO.

Reference Source 89
December 14, 2009

STAY CONNECTEDNewsletter | RSS | Twitter | YouTube |
This site is owned and operated by 1999-2018. All Rights Reserved. All content on this site may be copied, without permission, whether reproduced digitally or in print, provided copyright, reference and source information are intact and use is strictly for not-for-profit purposes. Please review our copyright policy for full details.
volunteerDonateWrite For Us
Stay Connected With Our Newsletter